PRISYM ID, a provider of data-led label and artwork management solutions announced its PRISYM 360 SaaS clinical trials labeling solution is live with customers and available to those pharmaceutical and trials organizations who need quick entry to clinical label printing.
To support the life sciences sector’s response to Covid-19, PRISYM ID is offering a cloud-based, ready to use version of its clinical trials SaaS labeling platform including a pre-validated pack with industry standard print processes. It is fast to onboard, needs minimal IT input to set up and provides certainty to the market in these uncharted times.
Being pre-validated, the application removes a significant proportion of the cost, time, and risk associated with implementing and validating a labeling system. It provides organizations with the control and agility needed to remove risk for clinical trial printing processes. Key features of this version include:
Warren Stacey, SVP of Sales at PRISYM ID, commented, “With the life science industry working at exceptional speed to run trials and accelerate the speed at which they come to market, labeling may be something of an afterthought. Yet it is critical to the process. Generic labeling software may be a blunt tool when it comes to validation, version control, compliance, and navigating the nuances of the clinical trials supply chain. Our PRISYM 360 SaaS solution already has customers live in this space, and it offers clinical researchers an off-the-shelf platform that’s fit for purpose, validated and secure.”
Warren continued, “To help the cause, we are offering organizations who are responding to Covid-19 special provisions to speed up their ability to get access to the solution, with environments being set up in advance and a team waiting to onboard them.”
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.